Cargando…

Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations

With the aging population, an increasing number of older adults (> 65 years) will be affected by problematic opioid use and opioid use disorder (OUD), with both illicit and prescription opioids. Problematic opioid use is defined as the use of opioids resulting in social, medical or psychological...

Descripción completa

Detalles Bibliográficos
Autores principales: Dufort, Alexander, Samaan, Zainab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421190/
https://www.ncbi.nlm.nih.gov/pubmed/34490542
http://dx.doi.org/10.1007/s40266-021-00893-z
_version_ 1783749026360852480
author Dufort, Alexander
Samaan, Zainab
author_facet Dufort, Alexander
Samaan, Zainab
author_sort Dufort, Alexander
collection PubMed
description With the aging population, an increasing number of older adults (> 65 years) will be affected by problematic opioid use and opioid use disorder (OUD), with both illicit and prescription opioids. Problematic opioid use is defined as the use of opioids resulting in social, medical or psychological consequences, whereas OUD is a form of problematic use that meets diagnostic criteria as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Problematic use of opioids by older adults is associated with a number of pertinent adverse effects, including sedation, cognitive impairment, falls, fractures and constipation. Risk factors for problematic opioid use in this population include pain, comorbid medical illnesses, concurrent alcohol use disorder and depression. Treatment of OUD consists of acute detoxification and maintenance therapy. At this time, there have been no randomized controlled trials examining the effectiveness of pharmacological interventions for OUD in this population, with recommendations based on data from younger adults. Despite this, opioid agonist therapy (OAT) is recommended for both stages of treatment in older adults with OUD. Buprenorphine is recommended as a first line agent over methadone in the older adult population, due to a more favourable safety profile and relative accessibility. Use of methadone in this population is complicated by risk of QT interval prolongation and respiratory depression. Available observational data suggests that older adults respond well to OAT and age should not be a barrier to treatment. Further research is required to inform treatment decisions in this population.
format Online
Article
Text
id pubmed-8421190
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-84211902021-09-07 Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations Dufort, Alexander Samaan, Zainab Drugs Aging Review Article With the aging population, an increasing number of older adults (> 65 years) will be affected by problematic opioid use and opioid use disorder (OUD), with both illicit and prescription opioids. Problematic opioid use is defined as the use of opioids resulting in social, medical or psychological consequences, whereas OUD is a form of problematic use that meets diagnostic criteria as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Problematic use of opioids by older adults is associated with a number of pertinent adverse effects, including sedation, cognitive impairment, falls, fractures and constipation. Risk factors for problematic opioid use in this population include pain, comorbid medical illnesses, concurrent alcohol use disorder and depression. Treatment of OUD consists of acute detoxification and maintenance therapy. At this time, there have been no randomized controlled trials examining the effectiveness of pharmacological interventions for OUD in this population, with recommendations based on data from younger adults. Despite this, opioid agonist therapy (OAT) is recommended for both stages of treatment in older adults with OUD. Buprenorphine is recommended as a first line agent over methadone in the older adult population, due to a more favourable safety profile and relative accessibility. Use of methadone in this population is complicated by risk of QT interval prolongation and respiratory depression. Available observational data suggests that older adults respond well to OAT and age should not be a barrier to treatment. Further research is required to inform treatment decisions in this population. Springer International Publishing 2021-09-07 2021 /pmc/articles/PMC8421190/ /pubmed/34490542 http://dx.doi.org/10.1007/s40266-021-00893-z Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Dufort, Alexander
Samaan, Zainab
Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations
title Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations
title_full Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations
title_fullStr Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations
title_full_unstemmed Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations
title_short Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations
title_sort problematic opioid use among older adults: epidemiology, adverse outcomes and treatment considerations
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421190/
https://www.ncbi.nlm.nih.gov/pubmed/34490542
http://dx.doi.org/10.1007/s40266-021-00893-z
work_keys_str_mv AT dufortalexander problematicopioiduseamongolderadultsepidemiologyadverseoutcomesandtreatmentconsiderations
AT samaanzainab problematicopioiduseamongolderadultsepidemiologyadverseoutcomesandtreatmentconsiderations